Release kinetics and mitogenic capacity of collagen barrier membranes supplemented with secretome of activated platelets - the in vitro response of fibroblasts of the periodontal ligament and the gingiva

Eva-Maria Mozgan 1,5†, Michael Edelmayer 1,5†, Klara Janjić 2,5, Manuela Pensch 1,5, Michael B. Fischer 3,4, Andreas Moritz 2,5 and Hermann Agis 2,5*

Abstract

Background: Platelet preparations can stimulate the healing process and have mitogenic properties. We hypothesized that collagen barrier membranes (CBM), clinically used in guided bone regeneration and guided tissue regeneration, can serve as carriers for platelet secretome.

Methods: Secretome was generated from washed platelets and unwashed platelets (washed/unwashed PSEC) and lyophilized onto CBM. Overall appearance of CBM was evaluated by scanning electron microscopy. The impact of PSEC on cell attachment was measured based on fluorescence microscopy with DiI-labeled cells. To assess the release kinetics, supernatants of CBM were collected and medium was replaced at hour 1–48. The mitogenic effect was evaluated with periodontal fibroblasts. Furthermore, the release of total protein, platelet-derived growth factor (PDGF)-BB, and transforming growth factor (TGF) β1 was measured.

Results: CBM overall appearance and cell attachment was not modulated by PSEC. Supernatants taken after one hour induced a mitogenic response in fibroblasts and showed the highest levels of total protein, TGFβ1 and PDGF-BB. These effects decreased rapidly in subsequent supernatants. While supernatants of CBM loaded with unwashed PSEC induced a stronger mitogenic response than supernatants of CBM loaded with washed PSEC this difference between the PSEC preparations was not observed when cells were seeded on 48–hours-washed CBM.

Conclusions: CBM release platelet-derived factors in continuously declining release kinetics.

Keywords: Platelets, Collagen barrier membranes, Tissue engineering, Guided bone regeneration, Thrombocytes

Background

In guided tissue regeneration collagen barrier membranes (CBM) are used as scaffolds to provide structural support for repair cells and prevent the ingrowth of soft tissue into periodontal and bone defects [1–3]. The success of this approach depends on the regenerative capacity of the respective tissue. When healing is compromised, therapeutic approaches based on biologicals can support regeneration. CBM represent a promising carrier for bioactive molecules that stimulate the healing capacity as they are placed in the interface between soft and hard tissue defects where they can release factors and pharmaceuticals to target cells of both tissues [4, 5]. Platelets have been investigated for their capacity to stimulate oral tissue regeneration based on their key role in the wound healing cascade and their capacity to modulate inflammation [6–9].

* Correspondence: hermann.agis@meduniwien.ac.at
† Equal contributors
2 Department of Conservative Dentistry and Periodontology, School of Dentistry, Medical University of Vienna, Sensengasse 2a, 1090 Vienna, Austria
3 Austrian Cluster for Tissue Regeneration, Donaueschingenstr. 13, 1200 Vienna, Austria
Full list of author information is available at the end of the article

© The Author(s), 2017. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wound healing and bone regeneration are initiated by the formation of a blood clot. In these blood clots, activated platelets release a myriad of growth factors that stimulate migration and proliferation of repair cells [10–12]. Among these factors are platelet-derived growth factor (PDGF) isoforms and transforming growth factors-β1 (TGFβ1). PDGF-BB activates all three PDGF receptor isoforms: PDGFRαα, PDGFRαβ, and PDGFRββ. Based on its potent activity, PDGF-BB was approved for the clinical application in periodontal tissue regeneration [13, 14]. TGF-β1 induces matrix production and cell proliferation and can bind to collagen [15–21]. The finding of mitogenic effects of activated platelets induced the development of regenerative strategies based on platelet concentrates [6–9, 22].

Platelet-rich plasma and platelet-rich fibrin can stimulate bone and periodontal ligament regeneration based on the high growth factor content of platelets [23]. Although platelet preparations, such as platelet-rich plasma and platelet-rich fibrin have been intensively studied, their effect on oral tissue regeneration and the underlying cellular activities is not entirely clear. Recently, cell-free approaches based on cell secretome have been proposed for regenerative purposes [24]. In vitro studies have shown that the secretome of activated platelets is mitogenic and that the preparation protocol modulates their effect on cell function including differentiation of osteoblasts and osteoclasts [25, 26].

Collagen can bind growth factors and therefore clinically applied CBM represent a promising carrier for the secretome of activated platelets [15, 16, 19–21]. In vitro studies have shown that the preparation protocol of the secretome can modulate the effect of bone cells. In particular the presence of serum components in the platelet preparation can have a high impact as the secretome of washed platelets and unwashed platelets has different effects. How the presence of serum components affect the release kinetics from CBM is unknown. Here we aimed to reveal the mitogenic capacity of CBM loaded with two different platelet preparations, generated by an established protocol [25, 26]: Secretome of washed platelets (washed PSEC) and secretome of unwashed platelet preparations (unwashed PSEC) both preparations can stimulate proliferation [25, 26]. We evaluated if loading with washed and unwashed PSEC changes the morphology and cell attachment on the membrane. An established bioassay was applied to assess the mitogenic activity released from the CBM over time [27]. In addition, we assessed the release kinetics directly based on total protein, PDGF-BB, and TGFβ1. Finally, we evaluated if the bound PSEC activity differs between CBM loaded with washed and unwashed PSEC.

Methods
Preparation of washed PSEC and unwashed PSEC
Platelet concentrates were generated at the Clinic for Blood Group Serology and Transfusion Medicine, Medical University of Vienna (The protocol was approved by the Ethics Committee of the Medical University Vienna) by single donor platelet apheresis using the Trima Accel® Automated Blood Collection System (TerumoBCT, Lakewood, CO). Platelets were stored under constant agitation in platelet additive solution SSP+ (Macropharma, Tourcoing, France) containing 20–30% plasma and forwarded for scientific use after a period of up to 6 h post-production. To generate washed and unwashed PSEC, concentrates were divided into 2 units (Fig. 1a): For unwashed PSEC, platelet concentrates were activated with 2 U human thrombin/mL. After coagulation the preparations were centrifuged. For washed PSEC the platelet concentrates were centrifuged, resulting in a platelet pellet. The platelet pellet was washed with Tyrode buffer, resuspended in an equivalent volume of serum-free medium and activated with 2 U human thrombin/mL as described above. The supernatant was obtained after centrifugation. All supernatants were sterile-filtered and stored in aliquots at -80 °C. The stock solutions represent platelet concentrations of approximately 1 x 10⁹ platelets/mL.

Loading of CBM with washed PSEC and unwashed PSEC
CBM (BioGide™) were provided by Geistlich Pharma AG (Wolhusen, Switzerland). In brief, CBM were cut into specimens of 5 mm in diameter. These specimens were soaked with washed and unwashed PSEC and frozen at -80 °C. Lyophilization was performed using a Freeze dryer ALPHA 1–2 LDplus (Martin Christ, Osterode am Harz, Germany) at the Center for Physiology and Pharmacology, Medical University of Vienna.

Scanning electron microscopy evaluation of CBM
The overall appearance of the rough and smooth side of the CBM was evaluated by scanning electron microscopy (SEM). Therefore, the lyophilized CBM were observed using the TM-1000 table top system (Hitachi, Tokyo, Japan). The specimens were mounted on an aluminium stub and images were captured from both sides of the membranes (rough and smooth) at 15,000 V accelerating voltage at a 500-fold magnification.

Cell culture
After informed consent, fibroblasts were prepared from extracted third molars (The protocol was approved by the Ethics Committee of the Medical University Vienna). The donors had no previous history of dental inflammation. Fibroblasts were isolated as described previously [28]. In brief: Gingival fibroblasts (GF) were prepared...
Fig. 1 (See legend on next page.)
Cells were plated at 50,000 cells/cm² in 96-well plates. 3[H]thymidine incorporation assay and immunoassays for PDGF-BB and TGF-β GF and PDLF and bicinchoninic acid (BCA) assays, and

These supernatants were subjected to bioassays with one CBM specimen. Supernatants were collected and replaced with fresh medium at hour 1, 3, 6, 24, and 48.

Supernatants from CBM were generated by adding 30,000 cells/cm² to each well of the CBM. To assess the effect on proliferation, cells were pulse-labeled with 3[H]thymidine and cultured for 24 h on the CBM and pulse-labeled with BrdU for the last 6 h of exposure. The assay was performed according to the protocol of the manufacturer and data was normalized to cells that were exposed to unloaded CBM.

BrdU assays
Cells in serum-free α-minimal essential medium supplemented with antibiotics were plated at 30,000 cells/cm² onto the CBM loaded with washed and unwashed PSEC. Cells were cultured for 24 h on the CBM and pulse-labeled with BrdU for the last 6 h of exposure. The assay was performed according to the protocol of the manufacturer.

BCA assay
Supernatants of the CBM were evaluated using the BCA assay (Thermo Scientific, Rockford, IL, USA) according to the instructions of the manufacturer. In brief: BCA A and B were mixed 1:50 and 100 μL were added per 10 μL of the 1:10 diluted sample. After 30 min at 37 °C absorption was assessed in a photometer at 550 nm.

Immuoassays for PDGF-BB
To evaluate the release of platelet-derived factors from the CBM PDGF-BB was assessed in the supernatants by immunoassays. Supernatants from CBM were harvested and subjected to Enzyme-linked immunosorbent assay (ELISA) for PDGF-BB. The measurements were performed using the PDGF-BB ELISA kit (Peprotech, Rocky Hill, NJ, USA) according to the description of the manufacturer.

Immuoassays for TGFβ1
To assess the release of TGFβ1 from the CBM the supernatants were assessed using the respective immunoassay. Supernatants of CBM were harvested and subjected to ELISA for TGFβ1. The measurements were performed using the Human TGF beta 1 ELISA kit (Cohesion Biosciences, London, UK) according to the description of the manufacturer.

Statistical analysis
Data are given as mean ± standard deviation and area under the curve (AUC) calculations were performed in indicated experiments. Data were compared by
These data suggest that CBM loaded with washed and unwashed PSEC loaded periodontal ligament fibroblasts, respectively. Hour 6 induced a 1.42-fold and 3.84-fold increase in proliferation of gingival fibroblasts, respectively. Supernatants generated from CBM loaded with washed and unwashed PSEC in the subsequent supernatants of both membranes. Supernatants generated at hour 6 were incubated with supernatants of the membranes. DiI-labeled GF and PDLF were seeded onto the smooth side of the CBM which is the side facing the soft tissue when applied clinically. Cells appeared round on the CBM after 1 h. Over time cells became more flat as suggested by a fibroblast-like morphology. However, there was no significant difference between the numbers of fibroblasts attached to unwashed PSEC-loaded, washed PSEC-loaded, and the unloaded CBM after 1 h, 3 h, and 24 h of incubation. Overall, GF and PDLF behaved similar. These data suggest that loading CBM with unwashed and washed PSEC does not hinder cell attachment to the membranes.

Supernatants of unwashed PSEC-loaded CBM show a stronger mitogenic effect than washed PSEC-loaded CBM

To assess the released mitogenic activity of washed and unwashed PSEC-loaded CBM, GF and PDLF were incubated with supernatants of the membranes taken at hour 1, 3, 6, 24, and 48 (Fig. 2a). Our data show that supernatants of washed PSEC-loaded and unwashed PSEC-loaded membranes stimulate proliferation of GF and PDLF (Fig. 2b, c). Supernatants generated from washed PSEC and unwashed PSEC-loaded CBM induced an increase in the first hour in proliferation of GF and PDLF. The capacity to enhance proliferation rapidly decreases in the subsequent supernatants of both membrane preparations. Supernatants generated at hour 6 from CBM loaded with washed and unwashed PSEC induced a 1.15-fold and 2.70-fold increase in proliferation of gingival fibroblasts, respectively. Supernatants generated from washed and unwashed PSEC-loaded CBM at hour 6 induced a 1.42-fold and 3.84-fold increase in proliferation of periodontal ligament fibroblasts, respectively. These data suggest that CBM loaded with washed and unwashed PSEC rapidly release platelet-derived factors. Calculation of the AUC revealed that supernatants from CBM loaded with unwashed PSEC have a higher mitogenic capacity than supernatants of CBM loaded with washed PSEC. Taken together unwashed PSEC-loaded CBM show a stronger mitogenic effect than washed PSEC-loaded CBM.

Unwashed PSEC-loaded CBM release more protein, PDGF-BB, and TGFβ1 than washed PSEC-loaded CBM

Next we assessed the release of platelet-derived factors by measuring total protein, PDGF-BB, and TGFβ1 in the supernatant of washed and unwashed PSEC-loaded CBM, respectively (Fig. 3a). Measurement of total protein release revealed that the protein concentration in supernatants of CBM loaded with washed and unwashed PSEC in the first hour were 768 μg/mL and 11423 μg/mL, respectively (Fig. 3b). The protein content declined in the subsequent supernatants taken at hour 3, 6, 24, and 48. Evaluation of growth factor release based on PDGF-BB and TGFβ1 showed similar kinetics (Fig. 3c, d). The highest PDGF-BB concentration was observed in supernatants taken at hour 1. 0.61 ng/mL and 2.56 ng/mL PDGF-BB were observed in the supernatants of washed and unwashed PSEC-loaded CBM, respectively. Also the highest TGFβ1 levels were found in the supernatants taken at hour 1. 0.37 ng/mL and 3.54 ng/mL TGFβ1 were observed in the supernatants of washed and unwashed PSEC-loaded CBM, respectively. We found that the majority of growth factors was released within the first 6 h. Unwashed PSEC-loaded CBM release more protein, PDGF-BB, and TGFβ1 than washed PSEC-loaded CBM. This was further supported by calculations of the AUC.

CBM can maintain a mitogenic activity after 48 h washing

To assess if the PSEC-loaded CBM retain their mitogenic activity absorbed to the CBM, fibroblasts were seeded onto the loaded CBM that were washed for 48 h as described above (Fig. 4a). Proliferation of GF seeded onto the loaded CBM that were washed with PSEC and unwashed PSEC were 1.90-fold and 2.14-fold of the unloaded CBM, respectively (Fig. 4b). Proliferation of PDLF seeded onto washed and unwashed PSEC-loaded CBM was 2.52-fold and 2.87-fold of the unloaded CBM, respectively (Fig. 4c). While this increase reached the level of significance in PDLF it was not significant in GF. Our data suggest that CBM loaded with washed and unwashed PSEC can retain part of their mitogenic capacity also after 48 h washing procedure absorbed on the CBM surface.

Discussion

In guided bone regeneration and guided tissue regeneration CBM are used as scaffolds and barriers to support...
the healing process [1–3]. Research has focused on optimizing the material and structural properties. Recently, strategies that use these membranes as carriers for bioactive molecules have been proposed [5, 16, 20]. Here, we follow an approach where CBM are used as carrier for platelet-derived factors. This approach is based on the concept that CBM can bind growth factors [16, 20]. We found that CBM loaded with washed and unwashed PSEC induce a mitogenic response indicating a continuous declining release of PSEC from the CBM. However, they also retain mitogenic capacity adsorbed to the surface of the CBM.

Cell attachment to the surface of the CBM is an integral step in the early phase of the healing process. Therefore, it is crucial to understand how processing affects the morphology of the membrane and cell attachment. We observed attachment at hour 1, hour 3, and hour 24 to assess in particular early attachment, based on previous studies of cell attachment on titanium surfaces [29]. In our setting, where we lyophilized the CBM with washed and unwashed PSEC, neither appearance of the membrane nor the numbers of cells attached to the membranes were compromised.

Supernatants of CBM loaded with washed and unwashed PSEC taken after one hour increased $^{3}$H-thymidine incorporation an indicating proliferation. The effect on cell proliferation decreased rapidly in subsequent supernatants taken after 3, 6, 24, and 48 h. These results are in line with the release kinetics of total protein, PDGF-BB, and TGFβ1, and our previous studies on the release of prolyl hydroxylase inhibitors from CBM [5]. Protein levels, PDGF-BB levels, and TGFβ1 levels were high in the first hour and decreased in supernatants which were taken later suggesting that the majority of growth factors was washed out in the first hours of incubation. Overall, supernatants of unwashed PSEC-loaded CBM showed a stronger stimulation of cell proliferation than washed PSEC-loaded membranes and the growth factor concentration in the supernatants of unwashed PSEC-loaded CBM was higher than in supernatants of CBM loaded with washed PSEC, suggesting that loading the membranes with unwashed PSEC might be more effective than with washed PSEC. These data are in line with direct measurements of the growth factor release.

In this study we used washed PSEC and unwashed PSEC which contains PDGF-BB and TGFβ1. Both growth factors show similar release kinetics in this model. Recombinant human PDGF-BB with beta-tricalcium phosphate is applied in clinic to stimulate periodontal regeneration by enhancing cell proliferation and cell attachment via activation of all isoforms of the cellular PDGF receptor, namely PDGFRαα, PDGFR-αβ, and PDGFR-ββ [30–32]. However, recombinant human
PDGF-BB is rapidly released from the beta-tri calcium phosphate within 90 min [33]. Non-cross-linked bovine type I collagen loaded with PDGF-BB or GDF-5 improved bone healing and release of recombinant human PDGF-BB over several days [34, 35]. The membrane was loaded by soaking for 1 h in the growth factor solution. The CBM used in our study is a non-cross-linked collagen type I/III which was loaded with washed and unwashed PSEC by lyophilization. The differences in the release profiles might be due to the different preparation and loading technique as well as the different types of membranes used. Our results from the washed PSEC and unwashed PSEC loaded CBM show a burst-like release of proteins, PDGF-BB and TGF\(\beta\)1 within the first 6 h which is in line with the mitogenic effects of the supernatants in the bioassays.

Based on these findings one might suspect that the PSEC-loaded CBM release their entire mitogenic capacity within the 48 h observation period. However, our results show increased proliferation of PDLF that have been seeded onto the PSEC-loaded CBM after the 48 h period. The elevated proliferation levels of GF did not reach the level of significance. Taken together these results suggest that CBM can retain part of their mitogenic capacity. This finding is not surprising as CBM can bind TGF\(\beta\) activity [15, 16, 19–21]. Thus, it might be possible that growth factors of PSEC remain bound to the collagen membrane where they can stimulate cell proliferation. The two platelet preparations, washed and unwashed PSEC, did not show any difference in regard to the proliferation of cells seeded onto the CBM. Our findings suggest that while there is a continuous declining release CBM can adsorb PSEC activity.

It is unclear if this feature is a specific capacity of the CBM used in this study. Here we used a commercially available CBM (BioGide\textsuperscript{®}) as carrier for the washed and unwashed PSEC. This CBM is composed of type I and type III collagen of porcine origin and shows a bilayered structure [3, 36]. CBM with a different structure might show different release kinetics. Comparison of BioGide\textsuperscript{®} with the single-layered CBM BME-10X composed of bovine collagen I revealed different release kinetics of bisphosphonates from these membranes [4]. Clearly, platelets release other factors besides PDGF-BB and TGF\(\beta\)1 that induce mitogenic effects, including other PDGF isoforms such as PDGF-AB and other signalling molecules [37]. PDGF-BB is the major PDGF isoform in freeze-dried PRP, therefore we used it as a surrogate marker for the release of platelet-derived signal factors of the CBM in the direct release assays [38]. In the present study, the decrease in PDGF-BB and TGF\(\beta\)1 release over time was paralleled by a decrease in the overall protein and mitogenic capacity in the supernatant of the PSEC loaded CBM, suggesting that these released growth factors show similar release kinetics.

In our study we chose an in vitro approach to assess the biological activity and release kinetics of supernatants of activated platelets of CBM. The bioassays used to assess the mitogenic capacity of the CBM loaded with washed and unwashed PSEC were based on primary human fibroblasts of the gingiva and the periodontal ligament. One might argue that fibroblasts of the gingiva and the periodontal ligament only partly reflect the in vivo situation, as osteoblasts that are required to form new bone at the defect site were not included in the study. However, results from our previous study show that washed and unwashed PSEC stimulate proliferation of osteoblasts in a similar manner. These data, together with the fact that periodontal fibroblasts and osteoblasts express receptors for PDGF-BB and TGF\(\beta\)1, indicates that similar effects can be expected on proliferation of osteoblasts and that the applied bioassay based on primary oral fibroblasts represent a viable system to assess the mitogenic capacity of the CBM [39–41]. The present in vitro study is a pre-requisite for further in vivo studies to assess the impact of CBM loaded with supernatants of activated platelets. Freeze-dried PRP-coated collagen scaffolds - while being mitogenic in vitro - reduced...
proliferation in vivo [38]. Horimizu et al. suggested that this is caused by the fibrin gel [38]. In the present study we used supernatants from activated platelets without fibrin. Whether this approach is beneficial compared to PRP requires further preclinical studies. A potential clinical application represents compromised healing. Therefore preclinical studies should be designed to reveal if PSEC loaded CBM can be of benefit in aged individuals or under the impact of diabetes.

**Conclusion**

Our results show that CBM can be loaded with washed and unwashed PSEC to induce a mitogenic response. The PSEC-loaded CBM show continuously declining release kinetics of their growth factors and remain a surface-bound source of mitogenic capacity. While the released mitogenic capacity of CBM loaded with unwashed PSEC is stronger than in the CBM loaded with washed PSEC, the membrane associated mitogenic capacity does not differ between the two preparations. Further studies are required to investigate if these in vitro observations translate into enhanced periodontal regeneration in vivo.

**Acknowledgments**

The authors thank Geistlich Pharma for providing the CBM (BioGide®) for this study. The study was supported by grant 10–063 of the Osteology Foundation (Lucerne, Switzerland). The authors thank Christian Gruber and co-workers (Center for Physiology and Pharmacology, Medical University of Vienna) for help and advice with sample lyophilization. The authors do not have any conflict of interest to declare.

**Funding**

The authors thank Geistlich Pharma for providing the CBM (BioGide®) for this study. The study was supported by grant 10–063 of the Osteology Foundation (Lucerne, Switzerland).

**Availability of data and materials**

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Authors’ contributions**

EM and ME were involved in study design, investigation, data analysis, and writing the manuscript. KJ and MF were involved in investigation, data analysis, and writing the manuscript. MF and AM were involved in the study design, data interpretation, and manuscript preparation. HA was involved in study design, investigation, data analysis, writing, and submission of the manuscript. All authors read and approved the final manuscript.

**Competing interests**

The authors declare that they have no competing interests.

**Consent for publication**

Not applicable.

**Ethics approval and consent to participate**

The protocol was approved by the Ethics Committee of the Medical University Vienna (631/2007). Informed consent was obtained.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**References**

1. Schwarz F, Sahm N, Bieling K, Becker J. Surgical regenerative treatment of peri-implantitis lesions using a nanocrystalline hydroxyapatite or a natural bone mineral in combination with a collagen membrane: a four-year clinical follow-up report. J Clin Periodontol. 2009;36(9):807–14.

2. Zwahlen RA, Cheung UK, Zheng L, Chow RL, Li T, Shulinecchi B, Gratz KW, Weber FE. Comparison of two resorbable membrane systems in bone regeneration after removal of wisdom teeth: a randomized-controlled clinical pilot study. Clin Oral Implants Res. 2009;20(10):1084–91.

3. Behring J, Junker R, Walboomers XF, Chessnutt B, Jansen JA. Toward guided tissue and bone regeneration: morphology, attachment, proliferation, and migration of cells cultured on collagen barrier membranes. A systematic review. Odontontology. 2008;9(1):1–11.

4. Liao J, Meng Y, Zhai J, Wen C, Tan M, Tian A, Wang Y, Liang X. Physicochemical, pharmacologic, and in vitro cellular effects of loading collagen membranes with zoledronic acid. Int J Oral Maxillofac Implants. 2013;28(4):1027–36.

5. Hamid O, Pensch M, Agis H. Release kinetics of prolyl hydroxylase inhibitors from collagen barrier membranes. J Biomater Appl. 2014.

6. Hatakeyama I, Marukawa E, Takahashi Y, Omura K. Effects of platelet-poor plasma, platelet-rich plasma, and platelet-rich fibrin on healing of extraction sockets with buccal dehiscence in dogs. Tissue Eng Part A. 2014;20(3-4):874–82.

7. Sammartino G, Tia M, Gentile E, Maresni G, Claudio PP. Platelet-rich plasma and resorbable membrane for prevention of periodontal defects after deeply impacted lower third molar extraction. J Oral Maxillofac Surg. 2009;67(11):2369–73.

8. Ghanam S, Booms P, Orlovskia A, Kubesch A, Lorenz J, Rutkowski J, Landes C, Sader R, Kirkpatrick C, Choukroun J. Advanced Platelet-Rich Fibrin (A-PRF) - A new concept for cell-based tissue engineering by means of inflammatory cells. J Oral Implantol. 2014;40(6):670–9.

9. Kim TH, Kim SH, Sandoor DK, Kim YD. Comparison of platelet-rich plasma (PRP), platelet-rich fibrin (PRF), and concentrated growth factor (CGF) in rabbit-skin defect healing. Arch Oral Biol. 2014;59(5):550–8.

10. Agis H, Kandler B, Fischer MB, Watzek G, Gruber R. Activated platelets increase fibrinolysis of mesenchymal progenitor cells. J Orthop Res. 2009;27(7):972–80.

11. Gruber R, Karreth F, Kandler B, Fuerst G, Rot A, Fischer MB, Watzek G. Platelet-released supernatants increase migration and proliferation, and decrease osteogenic differentiation of bone marrow-derived mesenchymal progenitor cells under in vitro conditions. Platelets. 2004;15(1):29–35.

12. Cardaropoli G, Araujo M, Lindhe J. Dynamics of bone tissue formation in tooth extraction sites. An experimental study in dogs. J Clin Periodontol. 2003;30(9):809–18.

13. Gruber R, Karreth F, Fromlet F, Fischer MB, Watzek G. Platelets are mitogenic for periodontium-derived cells. J Orthop Res. 2003;21(5):941–8.

14. Gruber R, Varga F, Fischer MB, Watzek G. Platelets stimulate proliferation of bone cells: involvement of platelet-derived growth factor, microparticles and membranes. Clin Oral Implants Res. 2002;13(5):529–35.
15. Wang AV, Leong S, Liang YC, Huang RC, Chen CS, Yu SM. Immunobilization of growth factors on collagen scaffolds mediated by polyanionic collagen mimetic peptides and its effect on endothelial cell morphogenesis. Biomacromolecules. 2008;9(10):2929–36.

16. Miron R, Saulacic N, Buser D, Izuka T, Sculean A. Osteoblast proliferation and differentiation on a barrier membrane in combination with BMP2 and TGFbeta1. Clin Oral Investig. 2013;17(3):981–8.

17. Wang L, Wang T, Song M, Pan J. Rho plays a key role in TGF-beta1-induced proliferation and cytoskeleton rearrangement of human periodontal ligament cells. Arch Oral Biol. 2014;59(2):149–57.

18. Silveno-Ruiz KG, Martinez AE, Garlet GP, Barbosa CF, Silva JS, Ciacerelli RM, Valentini SR, Aba-Rached RS, Junior CR. Opposite effects of bFGF and TGF-beta on collagen metabolism by human periodontal ligament fibroblasts. Cytokine. 2007;39(2):130–7.

19. Caballe-Serrano J, Sawada K, Miron R, Bosshardt DD, Buser D, Gruber R. Collagen barrier membranes adsorb growth factors liberated from autogeneous bone chips. Clin Oral Implants Res. 2017;28(2):236–41.

20. Stahl A, Miron R, Bosshardt DD, Sculean A, Gruber R. Collagen Membranes Adsorb the Transforming Growth Factor-beta Receptor I Kinase-dependent Activity of Enamel Matrix Derivative. J Periodontol. 2016;87(5):583–90.

21. Paralak VM, Vukicevic S, Reddi AH. Transforming growth factor beta type 1 binds to collagen IV of basement membrane matrix: implications for development. Dev Biol. 1991;143(2):303–8.

22. Marx RE. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg. 2004;62(4):489–96.

23. Dohan Ehrenfest DM, Bielecki T, Jimbo R, Barbe G, Del Corso M, Inchingolo F, Sammartino G. Do the fibrin architecture and leukocyte content influence the growth factor release of platelet concentrates? An evidence-based answer comparing a pure platelet-rich plasma (P-PRP) gel and a leukocyte- and platelet-rich fibrin (L-PRF). Curr Pharm Biotechnol. 2012;13(7):1145–52.

24. Mildner M, Hacker S, Haider T, Gschwandtner M, Werba G, Baresi C, Zimmermann M, Golabi B, Tschachler E, Ankersmit HJ. Secretome of peripheral blood mononuclear cells enhances wound healing. PLoS ONE. 2013;8(3):e60103.

25. Agis H, Schroenner S, Skoriansz C, Fischer MB, Watzek G, Gruber R. Platelets increase while serum reduces the differentiation and activity of osteoclasts in vitro. J Orthop Res. 2013;31(10):1561–9.

26. Agis H, Stampfl B, Watzek G, Gruber R. Activated platelets increase proliferation and protein synthesis of human dental pulp-derived cells. Int Endod J. 2010;43(2):115–24.

27. Agis H, Hueber L, Pour Sadeghian N, Persch M, Gruber R. In vitro release of dimethylolxyloxyglycine and I-mimosine from bovine bone mineral. Arch Oral Biol. 2014;59(10):1024–31.

28. Agis H, Watzek G, Gruber R. Prolyl hydroxylase inhibitors increase the production of vascular endothelial growth factor by periodontal fibroblasts. J Periodontal Res. 2012;47(2):165–73.

29. Al Mustafa M, Agis H, Muller HD, Watzek G, Gruber R. In vitro adhesion of fibroblastic cells to titanium alloy discs treated with sodium hydroxide. Clinical Oral Implants Res. 2015;26(1):15–9.

30. Heldin CH. Targeting the PDGF signaling pathway in tumor treatment. Cell Commun Signal. 2013;11:97.

31. Tallquist M, Kazakas A. PDGF signaling in cells and mice. Cytokine Growth Factor Rev. 2004;15(4):205–23.

32. Chen PH, Chen X, He X. Platelet-derived growth factors and their receptors: structural and functional perspectives. Biochim Biophys Acta. 2013;1834(10):2176–86.

33. Young CS, Ladd PA, Browning CF, Thompson A, Bonomo J, Shockey K, Hart CE. Release, biological potency, and biochemical integrity of recombinant human platelet-derived growth factor-βB (rPDGF-BB) combined with Augment(TM) Bone Graft or GEM 21S beta-tricalcium phosphate (beta-TCP). J Control Release. 2009;140(3):250–6.

34. Yamano S, Haku K, Yamanaka T, Dai J, Takayama T, Shimota R, Tachi K, Ishioka M, Hanatani S, Karunagaran S, et al. The effect of a bioactive collagen membrane releasing PDGF or GDF-5 on bone regeneration. Int J Periodontics Restorative Dent. 2011;31(4):429–36.

35. Ishioka M, Hanatani S, Karunagaran S, et al. The effect of a bioactive collagen membrane releasing PDGF on bone regeneration. J Periodontal Res. 2012;47(2):165–73.

36. Wang AY, Leong S, Liang YC, Huang RC, Chen CS, Yu SM. Immobilization of growth factors on collagen scaffolds mediated by polyanionic collagen mimetic peptides and its effect on endothelial cell morphogenesis. Biomacromolecules. 2008;9(10):2929–36.

37. Horimizu M, Kawase T, Nakajima Y, Okuda K, Nagata M, Wolf IF, Yoshie H. An improved freeze-dried PRP-coated biodegradable material suitable for connective tissue regenerative therapy. Cytobiology. 2013;66(3):223–32.

38. Sanchez-Fernandez MA, Gallois A, Riedl T, Jurdic P, Holfack B. Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling. PLoS ONE. 2008;3(10):e3537.

39. Oates TW, Xie JF, Clinton S, Hoang AM, Graves DT, Cochran DL. PDGF-alpha receptor subunit expression down-regulated by L-1beta in human periodontal ligament cells. J Dent Res. 1998;77(10):1791–8.

40. Takemura A, Matsuda N, Kimura S, Fujiiwa T, Nakagawa I, Hamada S. Porphyromonas gingivalis lipopolysaccharide modulates the responsiveness of human periodontal ligament fibroblasts to platelet-derived growth factor. J Periodontal Res. 1998;33(7):401–7.